ALBO - Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation

• The expectation is that Mirum trades two-fold higher or more on regulatory approval of maralixibat for Alagille syndrome, and better than Albireo’s lackluster share price performance post-regulatory successes in PFIC.
• Regulatory approval for MIRM represents a significant clinical milestone and the first ever therapeutic option for Alagille syndrome. Current treatment is liver transplantation.
• The six-year follow-up data on maralixibat in Alagille syndrome should bode well for MIRM during the regulatory review process.
• I propose why MIRM may have the upper hand over ALBO as both vie for the lucrative addressable market for pediatric cholestasis therapeutics.

For further details see: